New disposable devices designed to reduce risk of tissue cross contamination
May 1, 2006 — /MARKET WIRE/ — SAN DIEGO,Calif. — Tulip BioMed, Inc., formerly known as Cell Bio-Systems, Inc. (OTC: CBSI), a developer of medical devices and patented technologies for the living tissue markets, including plastic, cosmetic, and orthopedic surgeries, today announced it has launched sales of its new disposable surgical instruments for the removal of soft tissue and fluid for the plastic surgery market after receiving U.S. Food and Drug Administration (FDA) 510(k) clearance for its cannula devices.
Tulip BioMed is introducing two new types of disposable surgical cannulas, in multiple tip configurations and sizes for aesthetic body contouring, where cannula lubricity and reducing the risk of cross contamination are critical. According to Tulip BioMed CEO Marc Pilkington, ease of manipulation and risks of cross contamination are closely linked to the lubricity of the cannula, the needle used in these procedures.
“The vast majority of cannulas are made from stainless steel and are repeatedly sterilized for reuse. Although stainless steel is thought of as polished and smooth, in reality, the microscopic surface of steel is porous and potentially destructive to living cell tissues,” said Pilkington. “Over time, through sterilization and repeated exposure to corrosives, this material can break down, become jagged, and trap tissue, increasing the risk of cross contamination. We’re solving these problems with disposable instruments that have a lubricious coating designed to slip easily through the tissue, increasing safety for both patient and doctor, and delivering better surgical performance as well.”
The instruments developed by Tulip BioMed are designed to solve contamination issues by eliminating reuse of liposuction, fat transfer and stem cell instruments, and, because of the lubricious coating, are planned to increase the ease of manipulation for re-injection procedures. Tulip BioMed’s disposable cannulas connect to any syringe via a patented “SuperLuerLok” design that holds it steady. Tulip BioMed also has a patent-pending on the process used to add the lubricious coating to the instruments. The products are marketed under the Tulip Disposable brand name.
Tulip BioMed products are manufactured to meet strict US FDA standards. These disposable instruments are designed to vastly reduce the risk of infection, yield more predictable results, and also offer a cost-effective resource for doctors because the one-time-use instruments can be billed as a component of a procedure. More info is available at www.tulipdisposable.com.
Dr. Robert Peters, director of research at Tulip BioMed, said, “As general surgery, orthopedic and cosmetic surgery markets grow with the aging of the baby boomers, we anticipate our markets will expand considerably. It’s time for better and safer alternatives than what surgeons are using now. “
About Tulip BioMed, Inc.
Tulip BioMed, Inc., formerly known as Cell Bio-Systems, Inc. (OTC: CBSI), is a Nevada corporation with operations based in San Diego, California. Founded in 2004, Tulip BioMed is a medical device, biotechnology company that manufactures and distributes patented technologies for the plastic and cosmetic surgery, biopsy, orthopedic surgery, stem cell therapy and other living tissue markets. Tulip BioMed is the exclusive licensee of patented syringe connection devices that use the worldwide recognized Tulip brand name. Tulip BioMed manufactures, markets, and distributes medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets. On the Web: www.tulipbiomed.com
Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed (“Tulip”) which is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as “expect(s),” “feel(s),” “believe(s),” “will,” “may,” “anticipate(s),” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed, Inc. that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Clearpoint Agency, Inc.
SOURCE: Tulip BioMed